A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
PHASE2
This clinical trial aims to evaluate the efficacy and safety of neoadjuvant...
Status
Not Yet Recruiting
Location
Affiliated Cancer Hospital and Institute of Guangzhou Medical Univercity
CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
PHASE3
This is a multicenter, randomized, open-label, non-inferiority Phase III cl...
Status
Recruiting
Location
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College